Perfusion scintigraphy in the assessment of autologous cell therapy in diabetic patients with critical limb ischemia
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
29750878
DOI
10.33549/physiolres.933868
PII: 933868
Knihovny.cz E-resources
- MeSH
- Transplantation, Autologous trends MeSH
- Leg diagnostic imaging MeSH
- Cell- and Tissue-Based Therapy trends MeSH
- Diabetes Mellitus, Type 2 diagnostic imaging therapy MeSH
- Diabetic Foot diagnostic imaging therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Perfusion Imaging methods MeSH
- Aged MeSH
- Technetium Tc 99m Sestamibi MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Technetium Tc 99m Sestamibi MeSH
Perfusion scintigraphy with technetium-99-methoxy-isobutyl-isonitrile ((99m)Tc-MIBI) is often used for assessing myocardial function but the number of studies concerning lower limb perfusion is limited. The aim of our study was to assess whether (99m)Tc-MIBI was an eligible method for evaluation of the effect of cell therapy on critical limb ischemia (CLI) in diabetic patients. (99m)Tc-MIBI of calf muscles was performed before and 3 months after autologous cell therapy (ACT) in 24 diabetic patients with CLI. Scintigraphic parameters such as rest count and exercising count after a stress test were defined. These parameters and their ratios were compared between treated and untreated (control) limbs and with changes in transcutaneous oxygen pressure (TcPO(2)) that served as a reference method. The effect of ACT was confirmed by a significant increase in TcPO(2) values (p<0.001) at 3 months after ACT. We did not observe any significant changes of scintigraphic parameters both at rest and after stress 3 months after ACT, there were no differences between treated and control limbs and no association with TcPO(2) changes. Results of our study showed no significant contribution of (99m)Tc-MIBI of calf muscles to the assessment of ACT in diabetic patients with CLI over a 3-month follow-up period.
References provided by Crossref.org